XuanZhu Bio-B (02575) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 51.772 million yuan, representing a year-on-year increase of 72.03%. Gross profit reached 33.369 million yuan, up 102.33% compared to the previous year. The loss attributable to owners of the parent company narrowed by 55.88% to 246 million yuan, with a loss per share of 0.53 yuan.

During the reporting period, the group implemented flexible and targeted commercial strategies to maximize the advantages of each marketed product and target market, achieving remarkable results. By the end of the reporting period, for the commercialization of its digestive system disease drug Anjiuwei®, the group adopted a distribution model combining provincial agents and refined investment recruitment. It established a cumulative internal sales team of 48 members and built a sales network covering over 90 distributors, extending to more than 2,000 medical institutions nationwide.

In the commercial promotion of its oncology drugs XuanYueNing® and XuanFeiNing®, the group pursued a direct sales strategy driven by both market and medical efforts. It formed a specialized commercial team of over 150 members, systematically advancing the domestic commercialization process of its marketed products.